Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 14670836 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Pi X, Yan C, Berk BC (2004) Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis. Circ Res 94, 362-9 14670836
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (mouse)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BLMVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  cow
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
no change compared to control static
laminar flow increase
MEK5 (human) no change compared to control static, MEK5 CA
ERK5 (human) no change compared to control static, DN ERK5
laminar flow ERK5 (human) increase DN ERK5

S473-p - Akt1 (mouse)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BLMVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  cow
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
no change compared to control static
laminar flow increase
MEK5 (human) decrease static
ERK5 (human) decrease static
laminar flow MEK5 (human) increase DN MEK5
no change compared to control static
LY294002 no change compared to control
laminar flow increase
LY294002 laminar flow inhibit treatment-induced increase

S112-p - BAD (mouse)
Orthologous residues
BAD (human): S75‑p, BAD (mouse): S112‑p, BAD (rat): S113‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BLMVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  cow
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
no change compared to control static
laminar flow increase
PKIA (human) no change compared to control static
laminar flow PKIA (human) increase
Downstream Regulation
 Effect of modification (function):  activity, induced
 Effect of modification (process):  apoptosis, inhibited
 Comments:  ERK5 activation -Bad phosphorylation

S136-p - BAD (mouse)
Orthologous residues
BAD (human): S99‑p, BAD (mouse): S136‑p, BAD (rat): S137‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BLMVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  cow
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
serum MEK5 (human) increase
MEK5 (human) increase
no change compared to control static
laminar flow increase
MEK5 (human) increase static, CA MEK5
ERK5 (human) decrease static, DN-ERK5
laminar flow ERK5 (human) decrease DN ERK5
LY294002 no change compared to control
MEK5 (human) no change compared to control CA MEK5
LY294002 MEK5 (human) MEK5 (human) augment treatment-induced decrease CA MEK5
Downstream Regulation
 Effect of modification (function):  activity, induced
 Effect of modification (process):  apoptosis, inhibited
 Comments:  ERK5 activation -Bad phosphorylation

T359-p - p90RSK (rat)
Orthologous residues
p90RSK (human): T359‑p, p90RSK iso2 (human): T368‑p, p90RSK (mouse): T348‑p, p90RSK iso3 (mouse): , p90RSK (rat): T359‑p, p90RSK (chicken): T377‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BLMVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  cow
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
no change compared to control static
laminar flow increase
MEK5 (human) no change compared to control static
ERK5 (human) no change compared to control static DN ERK5
laminar flow ERK5 (human) increase DN ERK5

S363-p - p90RSK (rat)
Orthologous residues
p90RSK (human): S363‑p, p90RSK iso2 (human): S372‑p, p90RSK (mouse): S352‑p, p90RSK iso3 (mouse): , p90RSK (rat): S363‑p, p90RSK (chicken): S381‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  BLMVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  cow
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
no change compared to control static
laminar flow increase
MEK5 (human) no change compared to control static
ERK5 (human) no change compared to control static DN ERK5
laminar flow ERK5 (human) increase DN ERK5


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.